Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck Maxalt migraine therapy NDA filing is imminent, company indicates.

  • News

Executive Summary

MERCK MAXALT NDA FILING FOR MIGRAINE TREATMENT PLANNED BY END OF JUNE, the company indicated. The NDA for Maxalt (rizatriptan) will encompass two dosage forms and two doses of Maxalt: 5 mg and 10 mg doses in a tablet formulation and a Rapidisc "wafer that disintegrates in the mouth" using R.P. Scherer's Zydis technology. The wafer offers a convenience benefit, Merck said; the company believes the two dosage forms are comparable. The 10 mg dose will "be recommended as the primary dose," Merck said.

Table

View full table

Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

See All
UsernamePublicRestriction

Register

PS030375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By